GRB2

Growth factor receptor-bound protein 2 · P62993 · GRB2 on Sugi Atlas →

8,030 patent compounds predicted against GRB2, 5,463 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Dactinomycin (SCHEMBL3844)	1.00	3/20
Dactinomycin (SCHEMBL3845)	1.00	3/20
Dactinomycin (SCHEMBL6152)	1.00	3/20
SCHEMBL1650567	1.00	3/20
Dactinomycin (SCHEMBL1073159)	0.92	3/20
SCHEMBL502640	0.86	3/20
Dactinomycin (SCHEMBL867979)	0.83	3/20
Dactinomycin (SCHEMBL1901167)	0.75	3/20
Dactinomycin (SCHEMBL72601)	0.71	3/20
Dactinomycin (SCHEMBL2190255)	0.71	3/20
Dactinomycin (SCHEMBL1821467)	0.66	3/20
Dactinomycin (SCHEMBL987923)	0.61	3/20
SCHEMBL1105429	0.46	3/20
SCHEMBL263980	1.00	1/20
SCHEMBL740393	1.00	1/20
SCHEMBL43861	0.76	1/20
SCHEMBL43862	0.76	1/20
SCHEMBL148122	0.76	1/20
SCHEMBL723839	0.76	1/20
SCHEMBL1575213	0.71	1/20

Clinical trials — most relevant to GRB2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Overcoming Endocrine Resistance in Metastatic Breast Cancer	PHASE3	UNKNOWN
Cinnamomum Cassia Effect on IGF1 and Metabolic Control in Patients With DM2 Without Glycemic Control Metformin Treated	PHASE3	COMPLETED
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML	PHASE2	RECRUITING
Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS	PHASE1/PHASE2	WITHDRAWN
Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer	PHASE2	COMPLETED
Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501）	PHASE2	RECRUITING
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy	PHASE2	COMPLETED
Selective Treatment According to Molecular Subtype of Prostate Cancer	PHASE2	UNKNOWN
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma	PHASE1/PHASE2	COMPLETED
Neoadjuvant GW572016 to Treat Breast Cancer	PHASE2	COMPLETED
Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC	PHASE2	COMPLETED
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer	PHASE1/PHASE2	COMPLETED
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer	PHASE2	COMPLETED
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2	PHASE1	COMPLETED
Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing	PHASE1	COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101	PHASE1	WITHDRAWN
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)	PHASE1	COMPLETED
Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery	EARLY_PHASE1	COMPLETED
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing	nan	RECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
K-RAS Oncogene Mutation in Patients With Advanced Non-Small Cell Lung Cancer Associated With Exposure to Wood Smoke and Tobacco Smoking: Therapeutic Implications	nan	COMPLETED
Clinical Study on the Application of 18F-HER2 Affibody PET Imaging in HER2-Expressing Breast Cancer	nan	RECRUITING
IRS Proteins and Trastuzumab Resistance	nan	COMPLETED
Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients	nan	UNKNOWN
Immune Cell Response to Stimuli	nan	RECRUITING
Evaluation of HER2-targeted Therapy for Gastric Cancer and Establishment and Verification of Monitoring System	nan	UNKNOWN
Long-term Outcome of HER2-amplified Metastatic Breast Cancer: A Retrospective Analysis	nan	UNKNOWN
Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer	nan	UNKNOWN
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins.	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a GRB2 binder may also engage these)

Protein	Name	Similarity
Q5R4J7	—	1.000	Q5R4J7 →
P62994	—	1.000	P62994 →
Q60631	—	1.000	Q60631 →
Q07883	—	0.998	Q07883 →
Q6GPJ9	—	0.995	Q6GPJ9 →
Q66II3	—	0.994	Q66II3 →
P87379	—	0.991	P87379 →
Q6YKA8	—	0.989	Q6YKA8 →
Q08012	—	0.986	Q08012 →
NCK1	SH2/SH3 adapter protein NCK1	0.956	landscape →
O55033	—	0.955	O55033 →
O43639	—	0.952	O43639 →
VAV1	Proto-oncogene vav	0.950	landscape →
Q99M51	—	0.949	Q99M51 →
Q08DN7	—	0.947	Q08DN7 →
Q9R0C8	—	0.947	Q9R0C8 →
P29355	—	0.945	P29355 →
P25911	—	0.944	P25911 →
P54100	—	0.942	P54100 →
Q95M30	—	0.942	Q95M30 →
HCK	Tyrosine-protein kinase HCK	0.941	landscape →
LYN	Tyrosine-protein kinase Lyn	0.937	landscape →
P50545	—	0.936	P50545 →
P27870	—	0.936	P27870 →
P08103	—	0.933	P08103 →
Q9UKW4	—	0.933	Q9UKW4 →
Q07014	—	0.932	Q07014 →
Q01621	—	0.931	Q01621 →
Q9XYM0	—	0.930	Q9XYM0 →
Q6EWH2	—	0.929	Q6EWH2 →